Clinical, immunological and genomic analysis of the post vaccinated SARS-CoV-2 infected cases with Delta derivatives from Maharashtra, India, 2021

Clinical, immunological and genomic analysis of the post vaccinated SARS-CoV-2 infected cases with Delta derivatives from Maharashtra, India, 2021

•Globally breakthrough infections have occurred post COVID-19 vaccinations.•Delta and delta derivatives predominated amongst the infected cases.•All the cases presented with mild disease and had very low mortality.•Covishield and Covaxin vaccination could able to prevent the severe disease.•Assessme...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Journal of infection 2022-07, Vol.85 (1), p.e26-e29
Hauptverfasser: Yadav, Pragya D., Sahay, Rima R., Agrawal, Sachee, Shete, Anita, Adsul, Balkrishna, Tripathy, Srikanth, Nyayanit, Dimpal A., Manrai, Manish, Patil, Deepak Y., Kumar, Sanjay, Marwah, Vikas, Sapkal, Gajanan N., Shastri, Jayanthi, Viswanathan, Rajlakshmi, Pandit, Priyanka, Mishra, Yogendra, Chavan, Smita, Joshi, Yash, Kumar, T Ajai, Majumdar, Triparna, Kumar, Abhinendra, Patil, Savita, Munshi, Renuka, Desai, Unnati, Kaushal, Himanshu, Suryawanshi, Annasaheb, Dudhmal, Manisha, Gawande, Pranita, Jain, Rajlaxmi, Waghmare, Ashwini, Kalele, Kaumudi, Vedpathak, Pratiksha, Yemul, Jyoti, Bodke, Poonam, Kore, Tejashri, Kakrani, A.L., Athavale, Prachi, Suryawanshi, Poonam, Patsute, Sudhir, Padbidri, Vikram, Awate, Pradip, Abraham, Priya
Format: Artikel
Sprache:eng
Schlagworte:
Antibodies, Viral
COVID-19 - prevention & control
Genomics
Humans
India - epidemiology
Letter to the Editor
SARS-CoV-2 - genetics
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:•Globally breakthrough infections have occurred post COVID-19 vaccinations.•Delta and delta derivatives predominated amongst the infected cases.•All the cases presented with mild disease and had very low mortality.•Covishield and Covaxin vaccination could able to prevent the severe disease.•Assessment of immune response demonstrated need for booster dose.
ISSN:0163-4453
1532-2742
DOI:10.1016/j.jinf.2022.04.014